New tool aims to make cancer treatment safer for seniors
NCT ID NCT07484932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new tool called TRTRM that predicts which older cancer patients are at high risk for severe side effects from treatment. Researchers will use the tool to adjust drug doses and monitoring for patients aged 65 and older with solid tumors. The goal is to see if this approach reduces serious side effects compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRTRM-guided risk-stratified treatment strategy
What this could lead to
If successful, this tool could help doctors personalize cancer treatment for older patients, reducing severe side effects while maintaining effectiveness.
What could go wrong
This is a relatively early-stage trial with 400 participants, and the tool may not work as well in broader populations or with newer cancer therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong SAR
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••